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Abstract PLGA nanoparticles, separately loaded with eto-
poside (ETN) and quercetin dihydrate (QDN), were pre-
pared by adapting the solvent diffusion (nanoprecipitation)
technique. The effect of formulation variables such as
amount of polymer, theoretical drug loading, surfactant
concentration, and aqueous and organic phase volumes on
particle size and entrapment efficiency, were systematically
studied. The optimal formulations obtained were of submi-
cron size (153.4±4.2 nm for ETN and 148.6±1.6 nm for
QDN) and with low polydispersity indices (0.058±0.02 for
ETN and 0.088±0.03 for QDN). The entrapment efficien-
cies were found as 63.88±1.5 % and 41.36±3.4 % for ETN
and QDN, respectively. The characterization of ETN and
QDN was done by measuring the zeta potential, TEM, and
DSC analysis. The comparison was made in respect of in
vitro cytotoxicity assay using cancer cell line A549 (human
lung adenocarcinoma epithelial cell line). The results
revealed significant increase in cytotoxicity in nanoparticle
formulations than their respective free drug. The compari-
son was also made with respect to cytotoxic activity of
individual drug and combination of drugs in the form of
free drugs as well as nanoparticles. The combination treat-
ment in the form of nanoparticles is found to produce best
results among the treatments used in cytotoxicity studies.
Keywords PLGA nanoparticles . Nanopreciptation
technique . Etoposide . Quercetin dihydrate . A549 cell line
1 Introduction
Molecular biology opened new vistas for cancer treatment
as new pathways and targets that are involved in cancer
induction and progression are becoming accessible. Cancer
development process is the net result of various interdepen-
dent events such as abnormal signal transduction and inter-
cellular communication mechanisms, biochemical
interactions leading to genetic instability, angiogenesis, in-
vasion, metastasis, and immune evasion. Each of these
events can serve as target. A multitargeting approach will
block the biochemical and physiological pathways that sup-
port cancer development at various levels thus rational for
combination therapy lies in the fact that a well-designed
combination will target more procancer mechanisms and
maximize the therapeutic benefit (Yance and Sagar 2006).
Angiogenesis is one of these key processes, responsible for
cancer progression. It is a prerequisite for tumor development
and metastasis. Judah Folkman in 1971 proposed “antiangio-
genesis” for producing tumor regression or slowing down the
tumor growth (Folkman 1971). Later, modern research on
tumor angiogenesis and therapeutic antiangiogenic agents has
excelled at par, in last 40 years. As a result of that, several
antiangiogenic agents are in clinical trials and some drugs like
bevacizumab (Avastin), a recombinant humanized anti-VEGF
monoclonal antibody (Jain et al. 2004; Ferrara et al. 2004; Kim
et al. 1993), was approved for the treatment of metastatic
colorectal cancer (Hurwitz et al. 2004) and non-small cell lung
cancer (Sandler et al. 2006) in combination with chemotherapy.
Initial clinical studies revealed that single antiangiogenic
agents are not much effective in advanced stage tumors.
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Instead these studies were helpful in establishing the princi-
ples related to combination regimes of antiangiogenics with
cytotoxic treatment (Gasparini et al. 2005) and as a result of
this, therapy combining cytotoxic agent and antiangiogenic
agent is undergoing vigorous research in recent times. On
the basis of this strategy, we tried to explore the benefit of
combination therapy of etoposide (cytotoxic agent) and
quercetin dihydrate (antiangiogenic agent) in comparison
with single agent therapy.
Etoposide [4'-Demethylepipodophyllotoxin 9-(4, 6-O-
Ethylidene-β-D-Glucopyranoside)], an antineoplastic agent,
is a semisynthetic derivative of podophyllotoxin. It inhibits
DNA topoisomerase II, thereby inhibiting DNA synthesis.
Etoposide is cell cycle dependent and phase specific, affect-
ing mainly the S and G2 phases. It has been used for
treatment of a wide variety of malignancies, including lung
cancer, germ-cell malignancies, leukemias, non-Hodgkins
lymphoma, Kaposi's sarcoma, soft tissue sarcomas, neuro-
blastoma, and gastric cancer (Jasti et al. 1995; Hande 1998,
2008). Common toxicities from etoposide include bone
marrow suppression, nausea, vomiting, and alopecia. At
very high doses, such as those used with bone marrow
transplantation regimens, mucositis liver toxicity, fever,
and chills may also occur. Palmar–plantar eruptions and
irritation of the anal canal, hypersensitivity reactions, in-
cluding vasomotor changes in the pulmonary and gastroin-
testinal systems have been associated with etoposide use.
The most serious adverse event associated with etoposide is
the development of acute myelogenous leukemia. In addi-
tion, resistance to etoposide arises through multiple mecha-
nisms like mutations at ser-1106 in the topoisomerase II
molecule. Rapid repair of DNA breaks caused by etoposide
reduce sensitivity to etoposide (Hande 2008).
Many natural compounds inhibit cancer by interfering
with one or more of the mechanisms that are central to
cancer progression. Many natural polyphenolic compounds
like (e.g., quercetin, genestein, and curcumin) have been
shown to have antiangiogenic properties in vitro and in vivo
(Boik 2001; Furness et al. 2005).
Quercetin (3,3′,4′,5,7-penthydroxy flavone) is an impor-
tant polyphenolic bioflavonoid, more specifically flavonol
and is found in many fruits and vegetables (Spoerke 2003;
Boik 2001). It has demonstrated various pharmacological
activities including antioxidant activity by scavenging free
radicals, prevention of atherosclerosis, and chronic inflam-
mation (Havesteen 1983; Corvazier and Maclouf 1985).
Quercetin has also shown anticarcinogenic activity to nu-
merous cancer cell types, including breast, leukemia, colon,
ovary and squamous cell, endometrial, gastric, and non-
small-cell lung (Painter 1998). Quercetin exhibited several
functions to be a potential anticancer compound. These
functions include cell cycle regulation, interaction with type
II estrogen binding sites, reversal of multidrug-resistance,
and blockage of cellular signal transduction which inhibits
the ras cascade and induces apoptosis (Yoshida et al. 1990;
Scambia et al. 1993; Kim et al. 1998; Xiao et al. 1998). In
Addition, quercetin effectively inhibits tyrosine kinase ac-
tivity (Levy et al. 1984). The role of polyphenolic com-
pounds in cancer chemoprevention and chemotherapy has
been extensively reviewed by Ramos (Ramos 2008).
Quercetin has been reported to show significant antiangio-
genic potential by inhibiting angiogenesis through multiple
mechanisms. These include interaction with the COX-2 and
lipoxygenase (LOX)-5 enzymes, the EGF receptor, the HER-
2 intracellular signaling pathway, and the NF-κB nuclear
transcription protein (Igura et al. 2001; Tan et al. 2003).
Beneficial combinations of quercetin with other antican-
cer drugs have been reported. A prostate cancer xenograft
model showed that quercetin could enhance the anticancer
effects of tamoxifen through antiangiogenesis (Ma et al.
2004). Quercetin has been shown to increase the therapeutic
efficacy of cisplatin both in vivo and in vitro. In mice
bearing human tumor xenografts, intraperitoneal treatment
with a combination of 20 mg/kg quercetin and 3 mg/kg
cisplatin led to a significantly reduced tumor growth com-
pared to treatment with either drug alone (Hofmann et al.
1990). In an another in vitro study using human ovarian and
endometrial cancer cell lines, addition of 0.01 to 10 μM
quercetin to cisplatin caused 1.5- to 30-fold potentiation of
the cytotoxic effect of cisplatin (Scambia et al. 1992) and
also protected normal renal tubular cells from cisplatin
toxicity (Kuhlman et al. 1998). Quercetin showed synergis-
tic activity with busulphan against human leukemia cell
lines (Hoffman et al. 1989). Addition of 1–10 μM quercetin
to adriamycin treatment led to a dose-dependent increase in
cytotoxicity compared with treatment with adriamycin alone
in cultured multidrug-resistant human breast cancer cell
lines (Scambia et al. 1994). Quercetin has also been shown
in vitro to increase the cytotoxic effect of cyclophosphamide
(Hofmann et al. 1988), and to decrease resistance to gemci-
tabine and topotecan (Sliutz et al. 1996).
One of the important concerns in chemotherapy is chances
of DNA damage in healthy bone marrow cells during treat-
ment with etoposide, without compromising the antitumor
potency of the drug. Cierniak and Kapiszewska (2002) and
Cierniak et al. (2004) investigated modulatory effect of quer-
cetin on DNA damage, and reported major protection against
etoposide-induced DNA damage in bone marrow cells.
Effects of prolonged administration of quercetin, causing
the decrease in genotoxicity of etoposide treatment, may
indicate that nutritional strategies for preventing or amelio-
rating the DNA damage in normal cells is possible (Cierniak
and Kapiszewska 2002; Cierniak et al. 2004). This literature
supports the selection of drugs for our investigations.
Further drugs administered in free forms may evoke
problems like toxicity. When such drugs are encapsulated
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in nanoparticles, they are able to change the biodistribution
properties of drugs and target the tumor tissue effectively.
They improve the therapeutic effects and reduce the side
effects of the formulated drugs. Poly(D,L-lactide-co-glyco-
lide) (PLGA) is FDA-approved biodegradable polymer,
which is used most often for sustained, controlled, and tar-
geted drug delivery (Desai et al. 1996; Fonseca et al. 2002).
It is reported that nanoparticles larger than 200 nm can be
mechanically filtered in the spleen while those smaller than
100 nm left the blood vessels through fenestrations in endo-
thelial lining (Stolnik et al. 1995; Tabata and Ikada 1990).
Thus to deliver drugs to tumor, by passive targeting by sur-
passing reticuloendothelial system, nanoparticles with rela-
tively small size in the range of 100–200 nm were desirable
(Song et al. 2008).
The main objective of the present study was to formulate
PLGA nanoparticles (NPs) below 200 nm, loaded with
etoposide (ET) and quercetin dihydrate (QD) individually.
These formulations can be co-administered as anticancer–
antiangiogenic combination. As they are separately loaded,
there lies an advantage of designing a dose according to
requirement. Passive targeting is expected to achieve by
maintaining the size of PLGA NPs below 200 nm. In addi-
tion to formulation, optimization is an effective method of
studying the significance of a number of variables. In vitro
drug release study and in vitro cell line studies such as
cytotoxicity assay were conducted using A549 cell line to
evaluate in vitro formulation performance in comparison to
the plain drug.
2 Materials and methods
2.1 Materials
PLGA 502H, (lactide/glycolide ratio 50:50, inherent viscos-
ity 0.22 dl/g) was obtained as a gift sample from Boehringer
Ingelheim, Germany. Etoposide (ET) was obtained as a gift
sample from Cadilla Pharma, Ahmedabad, India. Quercetin
dihydrate (extrapure grade; QD) was purchased from Sisco
Research Laboratories Pvt. Ltd., Mumbai, India.
Poloxamer-407 (Lutrol F-127) was obtained as a gift sample
from Sun Pharma Advanced Research Company Ltd.
(SPARC), Vadodara, India. Lung adenocarcinoma cell line
A549 was purchased from National Centre for Cell Science
(NCCS), Pune, India. (MTT) 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide was purchased from
HiMedia, India. All other chemicals and solvents used were
of analytical grade.
2.2 Preparation of nanoparticles
PLGA nanoparticles loaded with ET and QD (ETN and
QDN) were prepared by nanoprecipitation (solvent diffu-
sion) method (Mohanraj and Chen 2006). 100 mg of PLGA
polymer along with drug (ET or QD) dissolved in 6 ml
acetone and then poured in a controlled manner (0.3 ml/
min) into 12 ml of 0.25 % aqueous solution of Poloxamer-
407, with mild constant stirring. Spontaneous diffusion of
acetone to aqueous phase creates an interfacial turbulence
that leads to formation of nanoparticles. The resulting nano-
particle dispersion was further stirred to evaporate the or-
ganic phase for 3–4 h. The nanoparticles were recovered by
centrifugation (Sigma Centrifuge 3K30, Germany,
10,000 rpm, 20 min, 2 cycles), washed twice with distilled
water, redispersed, and lyophilized (Heto Drywinner, Den-
mark) with trehalose as cryoprotectant. Each batch was
prepared in triplicate.
The parameters considered for optimization were poly-
mer concentration, surfactant concentration, organic phase
volume, aqueous phase volume, and theoretical drug load-
ing. The entrapment efficiency and the particle size were the
response parameters for the optimization.
The above process parameters were optimized individu-
ally for ET and QD for getting the particle size below
200 nm with maximum drug entrapment efficiency (DEE)
as presented in Figs. 1 and 2, respectively, for ET and QD.
Unless otherwise mentioned, all the experiments were
Fig. 1 Typical particle size
distribution curve of ETN
formulation
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conducted by varying one of the parameters while keeping
all other parameters at a set of standard conditions which are
mentioned in preparation of nanoparticles.
2.3 Characterization of nanoparticle formulations
2.3.1 Particle size, particle size distribution, and zeta
potential measurement
The particle size measurements were performed using Mal-
vern Zetasizer Nanoseries (Malvern Instruments Ltd., Mal-
vern, UK), which evaluates mean diameter and size
distribution profiles along with Polydispersity indices
(PDI) of NPs by Dynamic Light Scattering based on Photon
Correlation Spectroscopy (PCS). The nanoparticulate dis-
persions were suitably diluted in redistilled water so that the
count rate of NPs lies in the range of 200 to 400 and
measurements were done at 25°C. The report is presented
in Figs. 1 and 2, respectively, for ET and QD. Zeta potential
of NPs was measured in redistilled water in same instrument
at 25°C following the same dilution as for size measure-
ment. Each measurement was done in triplicate.
The effect of optimization parameters which includes
polymer concentration, aqueous phase volume, surfactant
concentration, theoretical drug loading, and organic phase
volume on particle size of ETN and QDN is presented in
Fig. 3(a, b, c, d, and e, respectively).
2.3.2 Determination of entrapment efficiency
The amount of ET/QD entrapped in NPs was estimated by
suspending 10 mg of NPs in aqueous medium and recover-
ing the NPs pellet by centrifugation for 30 min at
20,000 rpm (Sigma 3 K30, Germany). It was then dissolved
in acetonitrile and the solutions were analyzed for ET and
QD content in UV-visible spectrophotometer (UV-vis Phar-
maspec, Shimadzu1700, Japan) at 283.5 and 368.0 nm,
respectively. The entrapment efficiencies of ET and QD
are calculated as percent ratio of actual amount of drug in
NPs to the total amount of drug incorporated in formulation.
2.4 Transmission electron microscopy
The morphology of the ETN and QDN was examined by
Transmission Electron Microscope (Philips Tecnai-20, Hol-
land). Before analysis, NPs were dispersed in de-ionized dis-
tilled water and one drop of the diluted dispersion was placed
on 200-mesh carbon-coated copper grid for observation. Two
percent uranyl acetate was used as staining agent for nano-
particles. The transmission electron microscopy (TEM) images
of ETN and QDN were shown in Figs. 4 and 5, respectively.
2.5 Differential scanning calorimetry
The physical state of ETandQD loaded in NPswas investigated
by differential scanning calorimetry (DSC; Mettler Toledo,
Switzerland). About 5 mg of sample of freeze-dried nanopar-
ticles, i.e., ETN and QDN, was heated from 50 to 350°C at a
heating rate of 10°C/min (Figs. 6 and 7). The DSC thermograms
were also obtained for drugs ET and QD, PLGA(50:50) (P), and
plain NPs (PN) which served as controls (Fig. 8).
2.6 In vitro drug release from ETN and QDN
In vitro release studies of ET and QD from PLGA NPs were
carried out at 37±2°C by dialysis bag diffusion technique.
Briefly, 2.0 ml of the aqueous nanoparticulate dispersion was
placed in cellulose dialysis bag (cut off 12000, HiMedia,
India) and immersed in the 20.0ml of pH 7.4 phosphate buffer
solution in recipient compartment and stirred at about 100 rpm
with magnetic stirrer. BSA (3 mg/ml) was added to pH 7.4
phosphate buffer used for the QD release study to stabilize the
drug in buffer. The samples from the recipient compartment
were withdrawn at predetermined time intervals and replaced
with the fresh release medium. The samples were analyzed for
the drug content using UV-vis spectrophotometer (UV-vis,
Shimadzu 1701, Japan). A control experiment to determine
the release behavior of the free drugs was also performed in
the same way using the drug solutions. All experiments were
performed in triplicate and average values were calculated.
The release profiles are presented in Fig. 9
Fig. 2 Typical particle size
distribution curve of QDN
formulation
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2.7 Cytotoxicity study by MTT assay
The in vitro cytotoxic activities of the nanoparticle formu-
lations (ETN and QDN) were investigated in comparison
with free drug solutions of ET and QD on A549 cancer cell
line. The comparison was also made with respect to
cytotoxic activity of single drug and combination of drugs
in the form of free drugs as well as nanoparticles. The IC 50
values were determined. The cell viabilities for predeter-
mined time duration were found by MTT assay method
reported by Mossmann (1983). In brief, A549 cells were
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Fig. 3 Effect of various processing parameters on mean particle size and DEE of ETN and QDN. a Amount of polymer; b aqueous phase volume; c
surfactant concentration; d theoretical drug loading; e organic phase volume
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10 % FBS at 37°C with 5 % CO2 in humidified air. Then
cultures in the exponential growth phase were trypsinized
and diluted in medium to give a total cell count of 5×104
cells/mL. The cell suspension was then transferred to 96-
well plate to ensure 5,000 cells/well and allowed to attach
overnight. The medium was changed with 100-μl medium
containing ET, QD, ETN, and QDN of different concentra-
tions (0.5, 5, 10, and 50 μM). The combinations of plain
drugs, etoposide and quercetin dihydrate (EQ) and of their
NP forms (EQN) were studied by using fixed concentration
of QD (10 μM) and ET concentration being varied at range
mentioned above. The free drugs ET and QD were dissolved
in dimethyl sulfoxide (DMSO), diluted with complete me-
dia. (The concentration of DMSO was different in the final
serial diluted media but was less than 1 %). Each formula-
tion dilution was assessed in triplicate. Three wells contain-
ing only cells suspended in complete medium were used as
controls for cell viability. After incubation for 24, 48, and
72 h, suspension was removed and the wells were washed
with PBS. 10 μl of MTT (5 mg/ml) and 90 μl of medium
were added and incubated for around 3–4 h. Then the media
containing MTT was removed, leaving the precipitate.
DMSO (100 μl) was added to the wells. Plate was observed
at 570 nm using microplate reader. The results for IC 50 are
presented in Fig. 10 while that of cell viability studies are
presented in Figs. 11, 12, and 13.
3 Results and discussion
3.1 Preparation of nanoparticles
Etoposide and quercetin dihydrate loaded PLGA nanopar-
ticles (ETN and QDN) were prepared successfully by nano-
precipitation method. In this study, the effect of five
preparation variables on the mean diameter and entrapment
efficiencies of ETN and QDN was investigated as shown in
Fig. 3 and discussed below.
3.1.1 Effect of PLGA concentration
The mean diameter of all formulations increased as the
amount of PLGA is increased from 50 to 200 mg
(Fig. 3a). This can be attributed to increase in viscosity of
organic phase with increase in the PLGA amount and thus
leads to slower diffusion rate of PLGA solution in aqueous
phase and formation of larger-size droplets which is also
related to increased drug entrapment efficiencies (EEs).
Another mechanism that can contribute in this effect is
insufficient surfactant to cover the surface of larger droplets
and also coalescence of droplets during the removal of
organic phase and subsequent aggregation of NPs.
The EE of ET increased significantly (p<0.05) with the
increase of PLGA concentration while the EE of QD though
shows same trend but is less as compared to ET. This
confirms that large NPs are associated with higher drug EEs.
3.1.2 Aqueous phase volume
Figure 3b shows that size of NPs decreases, as the aqueous
phase volume (containing Poloxamer-407) increased. This
happens because the amount of surfactant increases corre-
spondingly, resulting in reduction of interfacial tension.
The mean EEs of these two drugs decreased substantially
with the increase in aqueous phase volume. This must be due
to the amount of drugs partitioned into the organic phase
reduced during mixing of aqueous and organic phases. The
drug loss still increased during solvent evaporation as theW/O
volume ratio increased. This effect is more pronounced in case
of QD. WhenW/O volume ratio increased, the amount of QD
dissolved in the aqueous phase increases, resulting in less QD
retention in the organic phase to interact with PLGA
Fig. 4 Transmission electron micrograph of ETN
Fig. 5 Transmission electron micrograph of QDN
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molecules and then lower EE of QD. This phenomenon is
responsible for the lower EEs of QD as compared to ET.
3.1.3 Surfactant concentration
Figure 3c predicts that the mean diameter decreased with
increasing surfactant concentration. At higher concentration,
more molecules of surfactant can align themselves at inter-
face to reduce the interfacial tension efficiently, which
resulted in significant increase in shear stress at constant
external energy input promoting the formation of smaller
particles (Galindo-Rodriguez et al. 2004). However, with
the increase in surfactant concentration, the viscosity of
aqueous phase increases, which would result in size increase
due to decrease in net shear stress. In case of ET, the size of
NP decreased with increase in concentration of surfactant
probably due to dominance of former phenomenon. But in
case of QDN, when surfactant concentration was increased
above 0.5 %w/v, the size increased as depicted in Fig. 3c.
This may be due to dominance of the later phenomenon over
the former above this concentration of surfactant. Thus, the
decrease in EE of ET with the increase in surfactant concen-
tration is obviously due to decrease in particle size.
The trend exhibited by QD (Fig. 3c) can be explained by
the behavior of QD in different surfactant concentration. It
was observed that, at lower concentration, the QD comes
out of both phases and precipitate as the evaporation of
organic solvent progresses, resulting in very low EE
(12.73±3.2 %) but the increase in surfactant concentration
upto 0.5 % w/v maintains the QD in a state to interact with
Fig. 6 DSC curves of ET and ETN
Fig. 7 DSC curves of QD and QDN
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PLGA sufficiently, thus increasing the EE to 37.77±4.2 %.
But if the surfactant concentration is increased beyond this
level, the EE decreases because the high concentration of
surfactant can increase the solubility of QD in aqueous
solution.
Therefore, less QD molecules remained in the organic
phase to interact with PLGA molecules when both phases
were mixed.
3.1.4 Theoretical drug loading
Significant differences were observed in the size of the ETN
and QDN upon varying this parameter. Increased drug load-
ing resulted in a more viscous organic phase, thus an in-
crease in the size of NPs was observed. In the present
investigation, the low amounts of drug loading were found
optimum. When theoretical drug loading was increased
from 2.5 to 7.5 %, the EE was greatly affected (Fig. 3d).
Addition of excessive quantities of drugs during the nano-
precipitation process causes more drug loss due to limited
drug entrapment capacity of the polymer, hence EEs de-
creased accordingly.
3.1.5 Organic phase volume
The increase in the organic phase volume from 4 to 10 ml
leads to decrease in particle size and subsequent decrease in
EE. Particle size reduction was observed due to decrease in
the viscosity of system associated with more organic phase
volume, leading to formation of smaller particles. Decrease
in the EEs is caused due to increase in the cosolvency effect
of organic solvent for the drugs, thus enhancing the aqueous
phase concentrations of drugs, while lower drug concentra-
tion available for interaction with PLGA.
Fig. 8 DSC curves of P, PN, ET, ETN, QD, and QDN. The DSC curves are shown in sequence as they are appearing in the center of figure from
top to bottom
Fig. 9 Comparison of In vitro release profile of ETN and QDN with
the plain drugs ET and QD. (Mean±SD, n03)
Fig. 10 Comparison of IC 50 values (micromolars) for various
treatments
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3.2 Characterization of ETN and QDN
3.2.1 Particle size, particle size distribution, and zeta
potential measurement
The optimized ETN and QDN formulations exhibited mean
diameters 153.4±4.2 and 148.6±1.6 nm respectively. The
size distribution curves for ETN and QDN were represented
in Figs. 1 and 2, respectively. Both these curves reveal a
narrow size distribution and monodisperse unimodal sys-
tems which is also reflected by the PDI, i.e., 0.058±0.02 for
ETN and 0.088±0.03 for QDN. As the particle sizes are
falling in 100–200-nm range, passive targeting of drugs to
tumor is expected.
The zeta potential is an important parameter when con-
sidering the stability of the nanoparticles in vitro. The more
negative or positive values of zeta potential are related to
more stable particles, more repulsion between particles re-
duce the particle aggregation.
The zeta potential of drug-free nanoparticles (PN) was on
higher negative side (−30.2±0.6 mV) whereas the incorpora-
tion of ET and QD resulted in slight decrease in zeta poten-
tials. The zeta potential values of ETN and QDNwere −26.4±
1.9 and −27.0±0.7 mV, respectively. The negative zeta
potentials are beneficial in drug delivery and prolonging the
circulation time property.
3.2.2 Drug entrapment efficiencies
The drug EEs for optimized ETN and QDN formulations
were 63.88±1.5 and 41.36±3.4 %, respectively. At all levels
of study, the drug EE of QD is not improved much as
compared to ET, though both drugs are hydrophobic in
nature. The ease with which QD precipitates in unfavorable
conditions is responsible for low values of EE. Thus, only
hydrophobicity of the drug is not the sole deciding factor but
level of interaction with polymer PLGA must be given due
attention.
3.2.3 Transmission electron microscopy
TEM indicated uniform and spherical shape, discrete particles
without aggregation and appear to be smooth in surface mor-
phology with nano-size range. The TEMmicrographs (Figs. 4
and 5) show the diameters 133.65 nm for ETN and 113.14 nm
for QDN. These diameters were not in accordance with that
determined with PCS. This was mostly because of the differ-
ence in the mechanisms of the two methods. The TEM is
based on diffraction technique and the PCSmeasures radius of
hydrated particles based on scattering. Thus PCS usually
measures larger than their genuine diameters whereas sizes
derived from TEM might be considerably smaller than their
real diameters (Song et al. 2008).
3.2.4 Differential scanning calorimetry
DSC thermograms of free ET and QD as well as ETN and
QDN formulation were obtained to define the physical state
of the drugs in NPs. Figure 6 shows thermograms for ET and
ETN. DSC of ET has revealed evidence of thermal events in
the range of 190–210°C, and at 268°C prior to decomposi-
tion at about 290°C. The exotherm at 206°C suggested the














































































Fig. 13 Percent A549 cell viabilities after 72 h for various treatments
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350°C revealed endotherm at 268°C which was attributed to
the melting point of the newly formed etoposide (Jasti et al.
1995). But ETN had not shown such exothermic and endo-
thermic peaks, indicating that ET formulated in NPs existed
as an amorphous state or a solid solution.
Figure 7 shows thermograms for QD andQDN. DSC of QD
revealed endotherms at 117.31 and 322.32°C corresponding to
a dehydration reaction and the melting process, respectively.
Both these endothermic peaks are completely disappeared in
the thermogram for QDN. These results suggested that the drug
was dispersed throughout the polymer forming a high-energy
amorphous state. Figure 8 shows the thermograms for P, PN,
ET, ETN, QD, and QDN. These curves clearly support the
entrapment of the drugs in the polymer.
3.2.5 In vitro drug release from ETN and QDN
Figure 9 depicts the release profiles of ET and QD from
PLGA NPs (i.e., ETN and QDN). In comparison with the
plain drug solutions (ET and QD), there was a profound time
prolongation of drugs release from NPs. Nearly 100 % of
drugs were released from plain drug solutions approximate-
ly in 6 h. But only about 40 % of drugs released from NPs
after 24 h (96.98±2.3 and 87.08±1.9 % for ET and QD,
respectively, from free drug solutions at 6 h, 46.69±2.7 and
38.65±2.0 % for ET and QD from nanoparticles at 24 h).
The reason behind this prolongation of release time is at-
tributed to slow degradation of PLGA, therefore the release
of ET and QD from nanoparticles depends on drug diffusion
from PLGA surface and matrix as well as bulk erosion or
swelling of polymer (Mu and Feng 2003).
Moreover, drug release pattern from nanoparticles
showed burst-release of drugs during the first 2 h of study,
followed by a lag phase of relatively slow release, which is
also reported earlier (Mainardes and Evangelista 2005;
Gõmez-Gaete et al. 2007). The high initial burst can be
attributed to the immediate dissolution and release of drugs
adsorbed on the surface and diffusion of drugs located near
the surface of the nanoparticles.
According to the release curves, it may be concluded that
QD released slower than ET in both free-drug solutions and
their respective nanoparticles. This may be caused due to
poor aqueous solubility of QD in comparison to ET in
pH 7.4 phosphate buffer. The cumulative release percentage
of QD was found to be lower than that of ET at any time
point from their respective nanoparticles.
The kinetic analysis of drug release was performed by
subjecting the data to dissolution study models as represented
by Table 1. The result of kinetic analysis reveals that the
release of ET and QD from free drug solutions followed the
first order kinetics and from ETN and QDN followed Higuchi
model. This indicates the drug release from matrix type of
systems.
The mechanism of drug release from the nanoparticles was
determined using the Korsmeyer–Peppas model (Korsmeyer
et al. 1983; Peppas 1985 and Peppas and Sahlin 1989; Costa
and Lobo 2001). The data obtained from the drug release from
nanoparticles were analyzed according to following equation
of Korsmeyer–Peppas model.
Mt=M□ ¼ ktn
Where (Mt/M˳) is fraction of drug released, k is release
constant, and n is release exponent.
The results for this analysis are given in Table 2. The
value of the release exponent “n” indicates the release
mechanism (Fickian diffusion, case II transport, or anoma-
lous transport). In the present study, the limits considered
were n00.45 (indicates a classical Fickian diffusion-
controlled drug release) and n00.89 (indicates a case II
relaxation release transport; non-Fickian, zero-order re-
lease). Values of n between 0.45 and 0.89 can be regarded
as an indicator of both phenomena (drug diffusion in the
hydrated matrix and the polymer relaxation) commonly
called anomalous transport. From the release exponent val-
ues in the Korsmeyer–Peppas model for the release of ET
and QD from their respective NPs, it could be concluded
that the mechanism that led to the release of drugs was an
anomalous transport.
3.2.6 Cytotoxicity study by MTT assay
IC 50 values at 72-h incubation for ETN and QDN were
found significantly lower comparable to the reference drugs
ET and QD, respectively (Fig. 10). The comparison of the
IC 50 values for various treatments also shows that
Table 1 Correlation co-efficient for different dissolution models









ET 0.633 0.966 0.861 0.875
QD 0.743 0.910 0.911 0.858
ETN 0.808 0.856 0.959 0.840
QDN 0.873 0.918 0.984 0.904








ETN 0.974 0.571 7.194
QDN 0.911 0.714 4.187
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combination treatment (EQ) showed higher activity when
compared with individual drug treatments. The increased
cytotoxicity of etoposide by adding 50 μM Quercetin on
human Ewing's tumor cells is reported by Debes et al.
(2003). The combination in the form of nanoparticles
(EQN) exhibited even higher activity than the plain drug
combination (EQ).
There was an increase in cytotoxicity in case of ETN and
QDN at all time points (Figs. 11, 12, and 13) in comparison
to free drug but the effect was non-significant at 24 h (p>
0.05). In the same case, significant (p<0.01) differences in
cytotoxicities were found at 48 and 72 h. The combination
treatment EQ exhibited significantly lower cell viabilities (p<
0.05) as compared to individual drug treatment. The EQN
treatment was found to produce significant improvement in
cytotoxicity effect (p<0.05) compared with the free drug
combination (EQ) except for the results at 24 h where the
difference is insignificant. When the comparison is made
between the cytotoxic effect of ET with the EQN, extremely
significant (p<0.001) enhancement in cytotoxic effect due to
EQN is observed at 48 h and highly significant (p<0.01)
enhancement is observed at 24 and 72 h.
The greater antiproliferative activity of combination ther-
apy (EQ) may be attributed to additive effect of single drug
treatments. The significance of the difference in cytotoxicity
effect of free drugs and nanoparticulate formulation was
established at 72 h and not at 24 h. This may be due to the
sustained release of drugs from the nanoparticles which can
be well correlated with the results of in vitro release studies
in previous section. The combination treatment EQN is
found to produce far better results as compared to single
chemotherapeutic drug treatment i.e. ET alone.
4 Conclusion
The study demonstrates that the nanoprecipitation (solvent
diffusion) technique followed by lyophilization is a viable
technique to obtain PLGA NPs with mean particle size of
about 150 nm and good entrapment efficiencies (63.88±1.5
for ETN and 41.36±1.93 for QDN). The particle size and
%EE was influenced by formulation variables, which needs
to be optimized. The results of in vitro studies reveal that
encapsulating the drugs in the form of PLGA nanoparticles
led to the sustained release of the drugs as compared to
faster release of free form of drugs. The conclusion can be
drawn from the in vitro cytotoxicity studies performed using
MTT assay that combination treatment in the form of PLGA
NPs was found far better than any individual drug treatment.
The incorporation of drugs separately in PLGA NPs allows
one to modulate the dose of both drugs as per the require-
ment of patient. As the quercetin exhibits several supporting
mechanisms in improving the efficacy of antineoplastic
drugs, there can also be a need to sequence the administra-
tion of both agents or combination regimen may be deliv-
ered simultaneously. In any respect, the formulations
obtained in this study can be very well utilized for extracting
maximum benefit for patients. Thus the results of our inves-
tigations clearly hold promise for the evaluation of combi-
nation treatment in the form of PLGA nanoparticles in vivo.
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